Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
TLDR
Four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications are summarized as a guide to discover additional HDAC inhibitor-based therapies with greater therapeutic utility.Abstract:
Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from histones and regulate expression of tumor suppressor genes. They are implicated in many human diseases, especially cancer, making them a promising therapeutic target for treatment of the latter by developing a wide variety of inhibitors. HDAC inhibitors interfere with HDAC activity and regulate biological events, such as cell cycle, differentiation and apoptosis in cancer cells. As a result, HDAC inhibitor-based therapies have gained much attention for cancer treatment. To date, the FDA has approved three HDAC inhibitors for cutaneous/peripheral T-cell lymphoma and many more HDAC inhibitors are in different stages of clinical development for the treatment of hematological malignancies as well as solid tumors. In the intensifying efforts to discover new, hopefully more therapeutically efficacious HDAC inhibitors, molecular modeling-based rational drug design has played an important role in identifying potential inhibitors that vary in molecular structures and properties. In this review, we summarize four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility.read more
Citations
More filters
Journal ArticleDOI
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
TL;DR: The research thus far on HDACi in combination therapy, with other anticancer agents and their translation into preclinical and clinical studies is summarized and potential biomarkers to either select or predict a patient’s response to these agents are discussed, in order to limit the off-target toxicity associated withHDACi.
Journal ArticleDOI
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Céline Berthon,Emmanuel Raffoux,Xavier Thomas,Norbert Vey,Carlos Gomez-Roca,Karen Yee,David Taussig,David Taussig,Keyvan Rezai,Christophe Roumier,Patrice Herait,Carmen Kahatt,Bruno Quesnel,Mauricette Michallet,Christian Recher,François Lokiec,Claude Preudhomme,Hervé Dombret +17 more
TL;DR: The once-daily recommended dose for oral, single agent oral OTX015 use in patients with acute leukaemia for further phase 2 studies is 80 mg on a 14 days on, 7 days off schedule.
Journal ArticleDOI
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim,Anastasios Stathis,Mary Gleeson,Sunil Iyengar,Valeria Magarotto,Xavier Leleu,Franck Morschhauser,Lionel Karlin,Florence Broussais,Keyvan Rezai,Patrice Herait,Carmen Kahatt,François Lokiec,Gilles Salles,Thierry Facon,Antonio Palumbo,David Cunningham,Emanuele Zucca,Catherine Thieblemont +18 more
TL;DR: The recommended dose of OTX015 in patients with haematological malignancies was established, with DLTs of thrombocytopenia, gastrointestinal events, fatigue, and hyponatraemia in 11 of 18 evaluable patients, and the Safety Monitoring Committee decided to establish the feasibility of 80 mg once a day on a continuous basis.
Journal ArticleDOI
Bromodomains: a new target class for drug development
TL;DR: The current state of BET inhibitor biology is reviewed, the next wave of bromodomain inhibitors with clinical potential in oncology and non-oncology indications are discussed, and the lessons learned from BET inhibitor programmes should affect efforts to develop drugs that target non-BET bRomodomains and other epigenetic readers.
Journal ArticleDOI
Drosophila as an In Vivo Model for Human Neurodegenerative Disease
TL;DR: There are many distinct fly models for a range of neurodegenerative diseases; this work focuses on select studies from models of polyglutamine disease and amyotrophic lateral sclerosis that illustrate the type and range of insights that can be gleaned.
References
More filters
Journal ArticleDOI
Chromatin Modifications and Their Function
TL;DR: The surface of nucleosomes is studded with a multiplicity of modifications that can dictate the higher-order chromatin structure in which DNA is packaged and can orchestrate the ordered recruitment of enzyme complexes to manipulate DNA.
Journal ArticleDOI
Anticancer activities of histone deacetylase inhibitors.
TL;DR: Recent advances in the understanding of the molecular events that underlie the anticancer effects of HDAC inhibitors are summarized and how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs are discussed.
Journal ArticleDOI
Apoptosis: a link between cancer genetics and chemotherapy.
TL;DR: Understanding the molecular events that contribute to drug-induced apoptosis, and how tumors evade apoptotic death, provides a paradigm to explain the relationship between cancer genetics and treatment sensitivity and should enable a more rational approach to anticancer drug design and therapy.
Journal ArticleDOI
Two pathogenetic types of endometrial carcinoma
TL;DR: The author presents a hypothesis that the complex of endocrine and metabolic disturbances arising long before the development of endometrial carcinoma determines the biological peculiarities of the tumor, its clinical course, and the prognosis of the disease.
Journal ArticleDOI
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.
TL;DR: Results clearly indicate that TSA is a potent and specific inhibitor of the histone deacetylase and that the in vivo effect of TSA on cell proliferation and differentiation can be attributed to the inhibition of the enzyme.